GXEA Stock Chart & Stats
€25.40
-€0.60(-2.38%)
At close: 4:00 PM EDT
€25.40
-€0.60(-2.38%)
Day’s Range― - ―
52-Week Range€22.40 - €29.40
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€1.73B
Enterprise Value-€451.30M
Total Cash (Recent Filing)€2.24B
Total Debt (Recent Filing)€6.36M
Price to Earnings (P/E)2.9
Beta0.21
Next Earnings
Nov 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.05
Shares Outstanding65,897,070
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.61Price Target Upside24.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.58
Revenue Forecast (FY)€28.42M
Bulls Say, Bears Say
Bulls Say
Very Strong Balance SheetMinimal leverage and a large equity base provide substantial financial flexibility for a biotechnology company pursuing clinical development and strategic transactions. This balance-sheet strength can help fund operations, absorb setbacks, and preserve options without relying heavily on external financing.
Strong Current ProfitabilityStrong TTM gross, operating, and net margins indicate that the company currently converts reported revenue into meaningful accounting profit. Improving net income supports internal funding capacity and gives management more resources to advance its portfolio, although consistency remains important.
Deep Liquidity And Portfolio ExpansionReaffirmed cash guidance and at least €1.6 billion of expected remaining cash provide a substantial runway for strategic transactions and development through potential gamgertamig approval. Adding autoimmune and inflammatory programs also broadens the future pipeline around immunology.
Bears Say
Persistent Cash BurnNegative operating and free cash flow despite reported profits raises questions about earnings conversion and the durability of internal cash generation. Continued cash consumption increases execution risk and makes future investment plans more dependent on the existing balance sheet.
Revenue VolatilityThe reversal from strong annual revenue growth to a TTM decline indicates that the current revenue base may be uneven rather than steadily compounding. Lower collaboration revenue can reduce operating visibility and make future profitability more dependent on portfolio progress.
Inconsistent Profitability QualityPast operating losses, negative net income, and inconsistent returns weaken confidence that the latest strong profitability will persist across development and portfolio transitions. This history makes execution and repeatability important risks even with current margins and liquidity.
Lakefront Biotherapeutics News
GXEA FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
Lakefront Biotherapeutics lowest stock price was €22.40 and its highest was €29.40 in the past 12 months.
What is Lakefront Biotherapeutics’s market cap?
Lakefront Biotherapeutics’s market cap is €1.73B.
When is Lakefront Biotherapeutics’s upcoming earnings report date?
Lakefront Biotherapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were Lakefront Biotherapeutics’s earnings last quarter?
Lakefront Biotherapeutics released its earnings results on Aug 10, 2026. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of -€0.734 by €0.764.
Is Lakefront Biotherapeutics overvalued?
According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Undervalued.
Does Lakefront Biotherapeutics pay dividends?
Lakefront Biotherapeutics does not currently pay dividends.
What is Lakefront Biotherapeutics’s EPS estimate?
Lakefront Biotherapeutics’s EPS estimate is -0.74.
How many shares outstanding does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Lakefront Biotherapeutics reported an EPS of €0.03 in its last earnings report, beating expectations of -€0.734. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
Currently, no hedge funds are holding shares in DE:GXEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lakefront Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€31.61 (24.44% Upside)
€31.61 (24.44% Upside)
Blogger Sentiment
Bullish
DE:GXEA Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.61%
12-Months-Change
Fundamentals
Return on Equity
19.58%
Trailing 12-Months
Asset Growth
-14.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lakefront Biotherapeutics
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
GXEA Stock 12 Month Forecast
Average Price Target
€31.61
▲(24.44% Upside)